TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06021457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-1
Description: Intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration
Study: NCT06131372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Participants will receive Cagrilintide subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Participants will receive Cagrilintide subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive semaglutide subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive semaglutide subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matched to cagrilintide or placebo matched to semaglutide subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to cagrilintide or placebo matched to semaglutide subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matched to cagrilintide or placebo matched to semaglutide subcutaneously.
Study: NCT06373822

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating-mirna
Description: A single blood sample (1 tube of 10 ml) on the day of the patient's visit to the service de Gynécologie of the CUSL.

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating-mirna
Description: A single blood sample (1 tube of 10 ml) on the day of the patient's visit to the service de Gynécologie of the CUSL.
Study: NCT06458322

Intervention type: OTHER
Intervention: Home dialysis or In-Center dialysis
Description: Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or in-center dialysis (hemodialysis)

Intervention type: OTHER
Intervention: Home dialysis or In-Center dialysis
Description: Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or in-center dialysis (hemodialysis)
Study: NCT06252129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subjects undergoing a lung specimen lymph node dissection
Description: A lobectomy specimen's resection will undergo systematic lymph node dissection either by the patient's treating thoracic surgeon and/or by a member of the pathology team.~The protocol for a standardized lymph node dissection consists of a series of blunt peribronchial dissections starting from the hilum to the periphery, with particular attention to points of airway bifurcation where intrapulmonary lymph nodes aggregate. By emphasizing the intrapulmonary lymph node map and a standardized dissection, the team will remove more lymph nodes from the lobectomy specimen, resulting in an accurate N staging.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Control group
Study: NCT05996159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QDOT MicroTM catheter
Description: Novel high power-short duration ablation catheter for atrial fibrillation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QDOT MicroTM catheter
Description: Novel high power-short duration ablation catheter for atrial fibrillation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-guided ablation only for PVI
Description: Ablation is the removal or destruction of something from an object by vaporization, chipping, erosive processes, or by other means.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-guided ablation only for PVI
Description: Ablation is the removal or destruction of something from an object by vaporization, chipping, erosive processes, or by other means.
Study: NCT06103838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluciclovine injection
Description: 370 MBq (10 mCi)(+/-20%) as a bolus intravenous injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Description: All participants will undergo 18F-FDG PET/CT within 30 days of the 18F-fluciclovine PET/CT scan
Study: NCT05957718

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TKTX cream
Description: TKTX cream was used in several studies on Tatto and laser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKTX cream
Description: TKTX cream was used in several studies on Tatto and laser
Study: NCT04340232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Subjects will receive a 2 mg oral dose of baricitinib.
Study: NCT05554510

Intervention type: OTHER
Intervention: Observational
Description: No interventions planned. Observational data collection only.
Study: NCT05936905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture 1 time per month

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic
Description: Chiropractic 1 time per month
Study: NCT06038578

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 5 mg/kg or 10 mg/kg IV infusion over 60 minutes on Day 1, 8, 15 and 21 of each 28 day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 5 mg/kg or 10 mg/kg IV infusion over 60 minutes on Day 1, 8, 15 and 21 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: 8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
Study: NCT05319925

Intervention type: OTHER
Intervention: Patient reported outcome measure
Description: Newly developed patient-reported instrument to measure financial effects of a cancer diagnosis and therapy of cancer patients in Germany
Study: NCT06544499

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod IV
Description: Intravenous infusion of efgartigimod

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod IV
Description: Intravenous infusion of efgartigimod

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Intravenous infusion of placebo
Study: NCT06038578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
Study: NCT05338086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB09 (denosumab biosimilar)
Description: PFS 60 mg/mL solution,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MB09 (denosumab biosimilar)
Description: PFS 60 mg/mL solution,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-Prolia
Description: PFS 60 mg/mL solution, administered as subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-Prolia
Description: PFS 60 mg/mL solution, administered as subcutaneous injection

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elemental Calcium
Description: at least 1000 mg daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Elemental Calcium
Description: at least 1000 mg daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Elemental Calcium
Description: at least 1000 mg daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: at least 400 IU daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: at least 400 IU daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: at least 400 IU daily
Study: NCT04950283

Intervention type: DIAGNOSTIC_TEST
Intervention: magnetic resonance examination, anthropometric and metabolic characterization
Description: Participants undergo a magnetic resonance examination, anthropometric characterization and metabolic characterization via oral glucose tolerance test.
Study: NCT05588206

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Stereotactic Radiotherap
Description: A standard 3+3 statistical design was employed. Three patients will initially be treated at dose level 1, 6 Gy in 5 fractions, 3 fractions a week. Dose limiting toxicities (DLT) were defined as any grade 3-5 radiation injury or any non-hematologic toxicity felt to be possibly, probably, or definitely related to radiation, identified within the evaluation period of 3 months following the completion of radiotherapy.
Study: NCT06503237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CART cells will be given IV at split doses.
Description: Split intravenous infusion of Anti-CD19 CART cells of (Dose escalating infusion of 1 - 6 x10\^6 CART cells/kg).
Study: NCT05007691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusal splint
Description: Occlusal splints are hard, made of polymer biocompatible material using digital additive technology.
Study: NCT05784571

Intervention type: OTHER
Intervention: Body Composition Assessment
Description: Assessment of body composition using bioelectrical impedance analysis.

Intervention type: OTHER
Intervention: Modified Physical Performance Test
Description: A test of physical functioning

Intervention type: OTHER
Intervention: Hand grip strength
Description: A test of hand grip strength using a hand dynamometer.

Intervention type: OTHER
Intervention: 6-minute walk test
Description: Self-paced test of walking capacity.

Intervention type: PROCEDURE
Intervention: Measurement of blood glucose and insulin
Description: Blood will be drawn for measurement of glucose and insulin.
Study: NCT06462157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compassionate Mind Training
Description: Participants will attend 6 x 90-minute online CMT sessions. CMT is delivered by combining taught information, exercises, and practices. It is effective, so the aim is to explore its use with menopausal women.
Study: NCT05088512

Intervention type: GENETIC
Intervention: SNP analysis of the DNA
Description: SNP analysis of the DNA obtained from peripheral blood sample

Intervention type: GENETIC
Intervention: SNP analysis of the DNA
Description: SNP analysis of the DNA obtained from peripheral blood sample
Study: NCT05077774

Intervention type: DEVICE
Group type: OTHER
Intervention: Harmony TPV System
Description: Harmony Transcatheter Pulmonary Valve (sizes 22 mm and 25 mm) and Harmony Delivery Catheter System (DCS)
Study: NCT06347211

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acumen IQ sensor with Hemosphere monitor incorporating the HPI algorithm
Description: Hemosphere monitoring and requires the use of a AcumenIQ sensor connected to an arterial line (Edwards Lifesciences Corp., Irvine, CA, USA). The sensor has a splitter which enables the splitting of the arterial blood pressure signal to facilitate a blood pressure signal on both the anesthesia machine monitor (standard care) and the HemoSphere monitor (study).~In the intervention arm we asked the anesthesiologist and anesthesia nurse to use the study treatment flowchart. If the HPI alarm goes off, which entails both a sound and a flickering light, we ask the anesthesiologist to act upon this alarm immediately. Use of the study treatment flowchart ensures that the anesthesiologist has to think about the underlying cause. The HemoSphere with HPI software has a second screen with variables that provide information about the underlying cause of the predicted hypotension.
Study: NCT05872906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: A 1.5-inch needle of 34 gauge (CASOON stainless steel acupuncture needles) is inserted. The physician will then locate the de qi location of the test subjects and elicit a de qi response accompanied by muscle twitch.
Study: NCT05662878

Intervention type: OTHER
Intervention: Assessment of Hand Strength and Spasticity
Description: Assessment of Hand Strength and Spasticity

Intervention type: OTHER
Intervention: Assessment of Hand Strength and Spasticity
Description: Assessment of Hand Strength and Spasticity
Study: NCT06584747

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET scan
Description: 18F-FDG PET scans will be performed to assess cerebral vascular reserve. For exams involving stimulation with Acetazolamide (DIAMOX®), the radiopharmaceutical injection (18F-FDG or 99mTc-HMPAO) will start exactly 15 minutes after the Acetazolamide (DIAMOX®) injection.
Study: NCT06212349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic-educational physiotherapy and pain education program
Description: The EG will carry out a total of 24 sessions, at a rate of 3 weekly sessions of 30 minutes each. The first session of each month will be in person and the rest will be done at home following video tutorials with an App (https://fisiotrack.com). The face-to-face sessions will be conducted by a women's health physiotherapist, and will consist on therapeutic exercises based on body awareness, motor control and respiratory awareness.They will also receive a pain education program with indications on pain education, as well as basic information and general advice on the positive effects of physical activity and a healthy lifestyle for endometriosis. In addition, biweekly supervision will be carried out via telephone or video conference by a specialized physiotherapist.
Study: NCT05066178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAS Treatment for Minimally Verbal Children with Autism
Description: Treatment involves principles of motor learning embedded in a naturalistic developmental milieu
Study: NCT05854160

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical Pulse Train Stimulation
Description: sEEG provides the ability to stimulate neural circuits via implanted electrodes by delivering mild intra-cranial electrical stimulations in different brain structures to estimate their impact on cognitive tasks.
Study: NCT05708976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Cognitive Behavioral Therapy (CBT) is a behavioral (psychotherapeutic) intervention for major depressive disorder (MDD). A highly trained masters' or PhD-level clinician will administer 8 weekly CBT sessions (\~50 minutes each), following the standard cognitive behavioral therapy for depression protocol.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Cognitive Behavioral Therapy (CBT) is a behavioral (psychotherapeutic) intervention for major depressive disorder (MDD). A highly trained masters' or PhD-level clinician will administer 8 weekly CBT sessions (\~50 minutes each), following the standard cognitive behavioral therapy for depression protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Whole-Body Hyperthermia (Active WBH)
Description: Active whole-body hyperthermia (active WBH) will be administered by trained research assistants. Preparation for the active WBH session, the active WBH session, and cool down will last 3.5 hours, with heating lasting approximately 90-100 minutes (and no longer than 140 minutes). The treatment will take place in an infrared sauna dome, and the active heating phase will last until the participants has achieved a core (rectal) temperature of 38.5 C.
Study: NCT06212349

Intervention type: OTHER
Group type: OTHER
Intervention: pain education program
Description: They will receive instructions on pain education, as well as basic information and general advice about the positive effects of physical activity and a healthy lifestyle for your endometriosis, in writing via email. In addition, they will receive biweekly supervision via telephone or video conference by a specialized physical therapist.
Study: NCT05708976

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Whole-Body Hyperthermia (Sham WBH)
Description: Sham whole-body hyperthermia (sham WBH) will be administered by trained research assistants. Preparation for the sham WBH session, the sham WBH session, and cool down will last 3.5 hours, with heating lasting approximately 90-100 minutes (and no longer than 140 minutes). The treatment will take place in an infrared sauna dome, and the sham WBH session will minimally impact core body temperature.
Study: NCT06309693

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum (QL) Block
Description: The standard of care QL block will be performed by the regional anesthesia team according to their standard protocol with a uniform quantity and concentration of analgesic agent. Patients will subsequently be asked about their pain postoperatively and opioid medication administration will be quantified.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Recovery After Surgical (ERAS) Protocol
Description: Subjects randomized to the ERAS arm will undergo the standard ERAS protocol of early postoperative ambulation, no bowel preparation, and the use of multimodal pain medications including acetaminophen and non-steroid anti-inflammatory drugs (NSAIDs). Patients will subsequently be asked about their pain postoperatively and opioid medication administration will be quantified.
Study: NCT05198323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT3001 Drug Product
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous infusion
Study: NCT05698888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP301
Description: VP301 is an afucosylated humanized Fc-modified immunoglobulin G1 (IgG1) bispecific antibody targeting CD38 and ICAM-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP301
Description: VP301 is an afucosylated humanized Fc-modified immunoglobulin G1 (IgG1) bispecific antibody targeting CD38 and ICAM-1.
Study: NCT04374253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Group 1 participants who were in the active arm in the double blind part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W. Participants who are naive to gantenerumab treatment will be required to undergo the 3 step uptitration scheme before receiving target dose of open label gantenerumab, 510 mg SC, Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Group 2 participants who have completed OLE part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W
Study: NCT05245929

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Distalization
Description: Distalizing the posterior maxillary segment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Distalization
Description: Distalizing the posterior maxillary segment
Study: NCT06532175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Su-Jok
Description: Su-jok seed therapy
Study: NCT06393049

Intervention type: OTHER
Group type: OTHER
Intervention: Hyperglycaemic clamp
Description: Following an overnight fast, the investigators will perform simultaneous samples from the arterial line, the venous line, and microdialysis and consider these samples as baseline values.~If the patient's blood glucose level is at 8-10 mmol/L at baseline, the investigators will not proceed with the intervention and instead evaluate if the intervention can take place the following day.~After baseline values are measured, intravenous glucose 20% (200g/1,000 ml) is infused to raise the glucose levels in both plasma and extravascular glucose compartments with approximately 3 mmol/L.
Study: NCT06635928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Description: 30min daily of 10.000 lux bright light therapy
Study: NCT04786444

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological Vaccine VLA1553
Description: Single intramuscular vaccination on Day 1 with one of three Lots of VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological Vaccine VLA1553
Description: Single intramuscular vaccination on Day 1 with one of three Lots of VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological Vaccine VLA1553
Description: Single intramuscular vaccination on Day 1 with one of three Lots of VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate
Study: NCT04873921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sterile kinesio taping
Description: Application area will be cleaned and dried prior to application to increase the adhesiveness of the tape and application will be done by an experienced physiotherapist during ACLR surgery.
Study: NCT04668248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation
Description: The simulation will consist of a one-time, short immersive simulation session at the STRATUS Center for Medical Education at BWH. The session will be conducted for up to one intern at the same time, in accordance with social distancing practices at BWH. This simulation session will consist of one short, hands-on scenario of simulated patient experiences with expert facilitators in the simulated hospital rooms to help providers identify when they are in the hot state and their reactions, and work on improving communication skills, differential diagnoses, and alternative therapeutic options. These scenarios are intended to simulate both in-person and virtual interactions that are common in the inpatient setting. During these trainings, we will use behavioral principles like time pressure and increasing cognitive load to simulate a hot state environment. After the scenarios, the facilitator will perform a debriefing session for the interns.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online educational training
Description: Providers assigned to the control arm will receive online educational training about other poorly-prescribed medications, including albumin, transfusion, and blood product repletion guidelines. This information will be in the form of electronically-delivered links to information already housed and available at BWH, including reviewing BWH guidelines and literature about transfusion reactions. The interns will be asked to answer several clinical questions about optimal prescribing. Albumin and related products are also high-risk medications often overprescribed on twilight shifts.